Don’t miss the opportunity to connect with our CEO @Jean-Philippe Combal & General Counsel & Head of Finance @Susan Coles at #BioEquity Europe 2024, from 12 – 14 May in San Sebastian, Spain!
🎤 Hear the latest developments on #Vivet’s diversified #GeneTherapy pipeline for rare liver metabolic diseases on 13 May at 17:15 CEST, where Jean-Philippe will present an update on the Company and its latest advancements, including lead clinical program, VTX-801 for the treatment of #WilsonDisease.
Schedule a 1-1 meeting with the team at BioEquity via the online partnering portal here https://bit.ly/3JJQ0r1 or reach out directly via LinkedIn.
📢 Listen in as our CEO @Jean-Philippe Combal joins a panel of key industry leaders at #BioEquity Europe 2024 to discuss and provide insights on ‘Scaling Up Europe’s Academic Engine in Cell and Gene Therapy.’
In the world of cell and gene therapies, strong, early clinical data from small academic studies have repeatedly catalyzed paradigm shifts that reverberate across industry. European physician-scientists have been at the forefront of several breakthroughs, including #CARTcells for #autoimmunity. But is that transformational value being captured by local ecosystems? What is the playbook for fostering and commercializing the translational leaps by Europe’s key industry leaders?
📅 Date & Time: Monday 13 May 2024 at 11:15 am CEST
📍 Location: Kursaal Elkargunea Center, San Sebastian
🎤 Panelists:
*Mark Kotter Founder & CEO – bit bio
*Dima Kuzmin, Managing Partner – 4BIO Capital
*Miquel Vila-Perello, CEO – SpliceBio
*Elisa Petris, Lead Partner – Syncona Investment Managment
*Jimmy Vanhove, CEO – Viralgen
For more than 20 years, Bio€quity Europe has been the event where CEOs and investors gather to network, partner, and debate critical issues facing the biotech industry.
